{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for amphotericin root_codes_comments in Code Comments (approximate match)
Status:
US Previously Marketed
Source:
21 CFR 310.545(a)(20) weight control corn syrup
Source URL:
First approved in 1942
Source:
M012
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
US Previously Marketed
Source:
Oil of Lavender U.S.P.
(1921)
Source URL:
First marketed in 1921
Source:
Oil of Lavender U.S.P.
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
BLA125786
(2024)
Source URL:
First approved in 2024
Source:
BLA125786
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
BLA125717
(2022)
Source URL:
First approved in 2022
Source:
BLA125717
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
M020
(2022)
Source URL:
First approved in 2022
Source:
M020
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
BLA125714
(2021)
Source URL:
First approved in 2021
Source:
BLA125714
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
M018
(2020)
Source URL:
First approved in 2020
Source:
M018
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/Over-the-CounterOTCDrugs/StatusofOTCRulemakings/ucm071835.htm laxative:stimulant laxative senna pod concentrate
Source URL:
First approved in 2019
Source:
LAXATIVES RUBILAX by Lydia Co., Ltd.
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
M022
(2013)
Source URL:
First approved in 2013
Source:
M022
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
NCT02065076: Phase 4 Interventional Completed Hyperkalemia
(2014)
Source URL:
First approved in 2013
Source:
21 CFR 352
Source URL:
Class:
STRUCTURALLY DIVERSE